- Home
- CGC vs AVIR Comparison
CGC vs AVIR Comparison
Compare CGC & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGC | AVIR |
|---|---|---|
| Founded | N/A | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.3M | 434.5M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CGC | AVIR |
|---|---|---|
| Price | $1.09 | $4.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 13.1M | 223.3K |
| Earning Date | 05-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.75 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | $12,759,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $15.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $2.46 |
| 52 Week High | $2.38 | $6.45 |
Technical Indicators
Market Signals| Indicator | CGC | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 28.59 |
| Support Level | $1.01 | $2.90 |
| Resistance Level | $1.10 | $4.80 |
| Average True Range (ATR) | 0.05 | 0.27 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 6.73 | 3.63 |
Price Performance
Historical ComparisonAbout CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.